AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27456597 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcrystalline cellulose nasal spray
Number of subjects: 20
Study 27456597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24720640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouch technique combined with connective tissue graft
Number of subjects: 40
Study 24720640 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap combined with connective tissue graft
Number of subjects: 40
Study 22749223 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone support stopped at week 5
Number of subjects: 220
Study 22749223 — intervention group
Group type: COMPARATOR
Intervention: Progesterone support stopped at week 8
Number of subjects: 220
Study 20656210 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 32
Study 20656210 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cognitive function assessment
Number of subjects: 32
Study 17388220 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride 180 mg once daily
Number of subjects: 254
Study 17388220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 15622228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral camera method
Number of subjects: 13
Study 15622228 — intervention group
Group type: COMPARATOR
Intervention: Graph paper method
Number of subjects: 13
Study 15622228 — intervention group
Group type: COMPARATOR
Intervention: Comparison of methods
Number of subjects: 13
Study 12187210 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy and placebo
Number of subjects: 1286
Study 12187210 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy and flutamide
Number of subjects: 1286
Study 10795758 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg intravenous) during normoglycemia (5-8.9 mmol/liter glucose)
Number of subjects: 14
Study 10795758 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg intravenous) during hyperglycemia (16-19 mmol/liter glucose)
Number of subjects: 14
Study 10795758 — intervention group
Group type: COMPARATOR
Intervention: Placebo during normoglycemia (5-8.9 mmol/liter glucose)
Number of subjects: 14
Study 10795758 — intervention group
Group type: COMPARATOR
Intervention: Placebo during hyperglycemia (16-19 mmol/liter glucose)
Number of subjects: 14
Study 8632217 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 100
Study 8632217 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 1485474 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg dipyridamole per day
Number of subjects: 32
Study 1485474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 4048888 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous centrifuged blood
Number of subjects: 20
Study 4048888 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed, packed red blood cells
Number of subjects: 20
Study 29265672 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand in Hand (HiH) intervention in addition to usual care
Number of subjects: 198
Study 29265672 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 198
Study 28363932 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire, Distress Thermometer Analogue Scale and PSYCHLOPS problem profile for monitoring depression, feedback of scores to patients by practitioners.
Number of subjects: 47
Study 28363932 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 47
Study 28363932 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire, Distress Thermometer Analogue Scale and PSYCHLOPS problem profile for monitoring depression.
Number of subjects: 47
Study 26232060 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent Mental Competency and Stress Management Training
Number of subjects: 68
Study 26232060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study 21704392 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 2708
Study 21704392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2708
Study 20840208 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based prevention programme
Number of subjects: 123235
Study 20840208 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123235
Study 18812486 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral DHEA 50 mg/d for 12 months
Number of subjects: 119
Study 18812486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 16480006 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical valve (Medtronic Hall or Medtronic ADVANTAGE)
Number of subjects: 40
Study 16480006 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological valve (Medtronic Mosaic or Medtronic Freestyle)
Number of subjects: 40
Study 16480006 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle stentless valve
Number of subjects: 40
Study 12928584 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% isoflurane concentration (C(I)iso)
Number of subjects: 16
Study 12928584 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% isoflurane concentration (C(I)iso)
Number of subjects: 16
Study 10633020 — intervention group
Group type: COMPARATOR
Intervention: Protemp II (control)
Number of subjects: 30
Study 10633020 — intervention group
Group type: EXPERIMENTAL
Intervention: Luxatemp, Provipont, or Triad‐VLC (experimental)
Number of subjects: 30
Study 9122311 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients (depressed)
Number of subjects: 3
Study 9122311 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients (non-depressed)
Number of subjects: 3
Study 9122311 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 3
Study 9122311 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients (both groups)
Number of subjects: 3
Study 8393272 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy (group A) including 60 mg/m2 of cisplatin (CDDP), 13 mg/m2 of Adriamycin (ADM), 150 mg of 5‐fluorouracil (5‐FU), Tamoxifen (TAM) 25 mg/m2 daily, and medroxyprogesterone acetate (MPA) 400 mg/m2 daily, administered orally and alternated every 4 weeks
Number of subjects: 30
Study 8393272 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B) receiving the same anticancer drugs without hormonal agents
Number of subjects: 30
Study 3737905 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplanar reconstruction (MPR)
Number of subjects: 30
Study 3737905 — intervention group
Group type: COMPARATOR
Intervention: Standard transaxial imaging
Number of subjects: 30
Study 29161531 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled levodopa (CVT-301) 25 mg
Number of subjects: 110
Study 29161531 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled levodopa (CVT-301) 50 mg
Number of subjects: 110
Study 29161531 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled levodopa (CVT-301) 35 mg (weeks 1-2)
Number of subjects: 110
Study 29161531 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled levodopa (CVT-301) 50 mg (weeks 3-4)
Number of subjects: 110
Study 29161531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 28009467 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT) for 10 weeks, including six online therapy lessons with content summaries and homework assignments
Number of subjects: 77
Study 28009467 — intervention group
Group type: COMPARATOR
Intervention: Monitored attention control (MAC) for 10 weeks
Number of subjects: 77
Study 28009467 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 77
Study 28009467 — intervention group
Group type: COMPARATOR
Intervention: Monitored attention control (MAC)
Number of subjects: 77
Study 25627338 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 461
Study 25627338 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 461
Study 25627338 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg or 100 mg (based on escape status)
Number of subjects: 461
Study 25627338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study 22981787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat-PAD (6-nmol dose, 4 administrations, 4 weeks apart)
Number of subjects: 0
Study 22981787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat-PAD (3-nmol dose, 8 administrations, 2 weeks apart)
Number of subjects: 0
Study 22981787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20390667 — intervention group
Group type: EXPERIMENTAL
Intervention: Health consequence message frame
Number of subjects: 315
Study 20390667 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondhand smoke message frame
Number of subjects: 315
Study 20390667 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry manipulation message frame
Number of subjects: 315
Study 20390667 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 315
Study 17938887 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized solution (1 IU/ml)
Number of subjects: 133
Study 17938887 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 133
Study 17938887 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized solution
Number of subjects: 133
Study 17053959 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide-induced natriuresis test
Number of subjects: 15
Study 17053959 — intervention group
Group type: COMPARATOR
Intervention: Volume expansion with saline and intravenous infusion of octreotide
Number of subjects: 15
Study 12754273 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (Escherichia coli 0113, 2 ng/kg)
Number of subjects: 6
Study 12754273 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 11063956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling by a registered dietitian
Number of subjects: 136
Study 11063956 — intervention group
Group type: COMPARATOR
Intervention: Dietary counseling by a physician only
Number of subjects: 136
Study 9042265 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha-beta A immunoreactive inhibin
Number of subjects: 39
Study 9042265 — intervention group
Group type: EXPERIMENTAL
Intervention: CA125
Number of subjects: 39
Study 9042265 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 39
Study 7538658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim (5, 10, or 20 microgram/kg/day SC)
Number of subjects: 12
Study 7538658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim (5 microgram/kg/day)
Number of subjects: 12
Study 7538658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim (2 microgram/kg/day)
Number of subjects: 12
Study 7538658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim (twice daily on alternate days)
Number of subjects: 12
Study 7538658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim therapy
Number of subjects: 12
Study 3262980 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of 1 ml of lignocaine (10 mg) to 19 ml of propofol
Number of subjects: 80
Study 3262980 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline added to 19 ml of propofol
Number of subjects: 80
Study 30969323 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit systolic blood pressure variability (BPV)
Number of subjects: 3912
Study 30969323 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit diastolic blood pressure variability (BPV)
Number of subjects: 3912
Study 30969323 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit pulse pressure variability (BPV)
Number of subjects: 3912
Study 30969323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative major adverse cardiovascular events
Number of subjects: 3912
Study 29197404 — intervention group
Group type: EXPERIMENTAL
Intervention: IBBIS mental health care integrated with IBBIS vocational rehabilitation
Number of subjects: 603
Study 29197404 — intervention group
Group type: EXPERIMENTAL
Intervention: IBBIS mental health care and standard vocational rehabilitation
Number of subjects: 603
Study 29197404 — intervention group
Group type: COMPARATOR
Intervention: Standard mental health care and standard vocational rehabilitation
Number of subjects: 603
Study 25868100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 51
Study 25868100 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA)
Number of subjects: 51
Study 25868100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 23432777 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylactic acid (PLA)
Number of subjects: 148
Study 23432777 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylamide hydrogel (PH)
Number of subjects: 148
Study 23432777 — intervention group
Group type: COMPARATOR
Intervention: Both PLA and PH
Number of subjects: 148
Study 21424272 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment supporter intervention (TS arm)
Number of subjects: 174
Study 21424272 — intervention group
Group type: COMPARATOR
Intervention: Standard adherence intervention package (non-TS arm)
Number of subjects: 174
Study 19200542 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 270
Study 19200542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day
Number of subjects: 270
Study 18074034 — intervention group
Group type: EXPERIMENTAL
Intervention: AS+SP+PQ
Number of subjects: 104
Study 18074034 — intervention group
Group type: COMPARATOR
Intervention: AS+SP
Number of subjects: 104
Study 15450786 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 14
Study 15450786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 14
Study 11439383 — intervention group
Group type: EXPERIMENTAL
Intervention: EHTS subjects
Number of subjects: 30
Study 9682999 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (ASP) 1000 mg/day (mean daily dose: 956 mg)
Number of subjects: 132
Study 9682999 — intervention group
Group type: COMPARATOR
Intervention: Flupentixol (FPX) 25 mg/day (mean daily dose: 22.6 mg)
Number of subjects: 132
Study 8562296 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (captopril or enalapril)
Number of subjects: 191
Study 8562296 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-ACE inhibitors)
Number of subjects: 191
Study 2108187 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP 0.1 microgram/kg
Number of subjects: 18
Study 2108187 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP 0.3 microgram/kg
Number of subjects: 18
Study 2108187 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP 1.0 microgram/kg
Number of subjects: 18
Study 2108187 — intervention group
Group type: COMPARATOR
Intervention: GHRH 1.0 microgram/kg
Number of subjects: 18
Study 2108187 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP 0.1 and 0.3 microgram/kg plus GHRH 1.0 microgram/kg
Number of subjects: 18
Study 120757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (maximum tolerated doses)
Number of subjects: 6
Study 120757 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 6
Study 30842065 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous testosterone genetically predicted by variants in the JMJD1C gene region
Number of subjects: 3225
Study 30842065 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted testosterone based on JMJD1C gene region variants
Number of subjects: 3225
Study 30842065 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone genetically predicted by potentially pleiotropic variants in the SHBG gene region
Number of subjects: 3225
Study 28385352 — intervention group
Group type: EXPERIMENTAL
Intervention: MLE4901 (40 mg, orally, twice daily)
Number of subjects: 37
Study 28385352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally, twice daily)
Number of subjects: 37
Study 26275583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU)
Number of subjects: 10
Study 26275583 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 10
Study 24083696 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 30
Study 24083696 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ringer's solution)
Number of subjects: 30
Study 24083696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ANH and Control groups
Number of subjects: 30
Study 24083696 — intervention group
Group type: EXPERIMENTAL
Intervention: ANH group
Number of subjects: 30
Study 21504872 — intervention group
Group type: EXPERIMENTAL
Intervention: MIDonline intervention (n = 110)
Number of subjects: 202
Study 21504872 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 92)
Number of subjects: 202
Study 17916806 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate 50/500 microg twice daily
Number of subjects: 1323
Study 17916806 — intervention group
Group type: COMPARATOR
Intervention: tiotropium 18 microg once daily
Number of subjects: 1323
Study 17916806 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate
Number of subjects: 1323
Study 17916806 — intervention group
Group type: COMPARATOR
Intervention: tiotropium
Number of subjects: 1323
Study 17070150 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-eluting stents
Number of subjects: 92
Study 17070150 — intervention group
Group type: COMPARATOR
Intervention: Control group (unloaded stents)
Number of subjects: 92
Study 12835986 — intervention group
Group type: EXPERIMENTAL
Intervention: Mangafodipir trisodium (5 micromol/kg)
Number of subjects: 923
Study 10958384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 15
Study 10958384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1923169 — intervention group
Group type: EXPERIMENTAL
Intervention: Outlet forceps delivery
Number of subjects: 333
Study 1923169 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous vaginal delivery
Number of subjects: 333
Study 7163513 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 0
Study 7163513 — intervention group
Group type: COMPARATOR
Intervention: Control (no oxytocin infusion)
Number of subjects: 0
Study 30599808 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantarflexor EMG during standing balance challenges
Number of subjects: 20
Study 30599808 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing challenge to standing balance
Number of subjects: 20
Study 30599808 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study 29806782 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable sound exposure
Number of subjects: 30
Study 29806782 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable sound exposure
Number of subjects: 30
Study 29806782 — intervention group
Group type: COMPARATOR
Intervention: Silence
Number of subjects: 30
Study 27114421 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Therapy (ST) for 10 days
Number of subjects: 601
Study 27114421 — intervention group
Group type: COMPARATOR
Intervention: Triple Therapy (TT) for 7 days
Number of subjects: 601
Study 25270152 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab as induction therapy after renal transplantation
Number of subjects: 0
Study 25270152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23147050 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic physical training program (PTP) on a treadmill, three times a week, for six weeks
Number of subjects: 36
Study 23147050 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic physical training program)
Number of subjects: 36
Study 20200306 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 176
Study 20200306 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline A1C levels
Number of subjects: 176
Study 20200306 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline blinded CGM
Number of subjects: 176
Study 20200306 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and insulin modality (pump vs multiple daily injections)
Number of subjects: 176
Study 17608776 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200 mug)
Number of subjects: 28
Study 17608776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16808313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerythritol compositum (20 mg of pentaerythritol tetranitrate and 0.5 mg of nitroglycerine)
Number of subjects: 20
Study 16808313 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine (0.5 mg)
Number of subjects: 20
Study 12011664 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 75 mg daily
Number of subjects: 18790
Study 12011664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18790
Study 10048059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound microneurosurgical unit
Number of subjects: 299
Study 7600846 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 0
Study 7600846 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 7600846 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary interventions (PTCA)
Number of subjects: 0
Study 7600846 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 0
Study 7600846 — intervention group
Group type: COMPARATOR
Intervention: Directional atherectomy and stenting
Number of subjects: 0
Study 7600846 — intervention group
Group type: COMPARATOR
Intervention: Elective stenting
Number of subjects: 0
Study 7600846 — intervention group
Group type: COMPARATOR
Intervention: Laser and rotational atherectomy
Number of subjects: 0